Interpace Biosciences, Inc. (OTCMKTS:IDXG) Shares Shorted: Short Interest Up 550.0% in October

Interpace Biosciences, Inc. (OTCMKTS:IDXG) was the recipient of a large growth in short interest during the month of October. As of October 30th, there was short interest totaling 13 shares, a growth of 550.0% from the October 15th total of 2 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 4,223 shares, the short-interest ratio is presently 0.0 days.

Interpace Biosciences Price Performance

IDXG opened at $7.00 on Wednesday. The firm has a 50 day simple moving average of $6.59 and a 200 day simple moving average of $8.03. Interpace Biosciences has a fifty-two week low of $4.95 and a fifty-two week high of $7.45.

Interpace Biosciences (OTCMKTS:IDXG) last released its quarterly earnings data on Monday, August 10th. The business services provider reported $0.05 earnings per share for the quarter. Interpace Biosciences had a net margin of 67.64% and a return on equity of 145.40%. The business had revenue of $9.13 million for the quarter.

Interpace Biosciences Company Profile

Interpace Biosciences, Inc. is a molecular diagnostics company focused on improving the diagnosis and management of cancer and other complex diseases. The company develops and commercializes molecular tests that help physicians evaluate disease risk, guide treatment decisions and reduce uncertainty associated with conventional diagnostic procedures. Its portfolio has included tests for thyroid, pancreatic and gastroesophageal conditions. ThyGeNEXT and ThyraMIR are designed to help evaluate indeterminate thyroid nodules, while PancraGEN supports risk assessment for pancreatic cysts.